Comparing three chemotherapy combinations for newly diagnosed blood cancer

This trial is testing three different chemotherapy approaches for newly diagnosed acute myeloid leukemia (AML), a serious blood cancer. Two of the approaches combine a drug called venetoclax with other chemotherapy medicines in different ways, while the third uses a standard chemotherapy combination. The study aims to find which approach works best and is safest for patients who are healthy enough to tolerate intensive treatment.

Current treatments for AML work well but can be hard on patients' bodies and hearts. Researchers want to find a balance between treatments that are effective at fighting the cancer and treatments that patients can tolerate better, especially by exploring how this medication might work better alongside other chemotherapy options.